Vemurafenib

The triplet combination of vemurafenib/cobimetinib/atezolizumab showed improvement in overall survival in patients with BRAF-mutated anaplastic thyroid cancer, according to research presented at American Thyroid Association Annual Meeting.

Vemurafenib plus rituximab induced durable complete responses in the majority of a small cohort of patients with relapsed or refractory hairy-cell leukemia, according to a phase 2 study published in The New England Journal of Medicine.

The addition of vemurafenib to irinotecan and cetuximab improved PFS and response rates among patients with BRAF V600E-mutant metastatic colorectal cancer, according to study results published in Journal of Clinical Oncology.

The FDA today approved atezolizumab plus cobimetinib and vemurafenib for the treatment of patients with BRAF V600-positive advanced melanoma, according to a manufacturer-issued press release.

The addition of atezolizumab to cobimetinib and vemurafenib significantly prolonged PFS and conferred durable responses among patients with BRAF V600 mutation-positive advanced melanoma, according to results of the randomized phase 3 IMspire150 study presented at the virtual American Association for Cancer Research Annual Meeting.

CHICAGO — The Wnt/beta-catenin signaling pathway may play an important role in the progression of BRAF V600E-mediated papillary thyroid cancer, according to study results presented at the Annual Meeting of the American Thyroid Association.